Novo Nordisk: The success story continues

Last Updated: 6. Februar 2024By

In October 2017, I introduced you to the stock of Novo Nordisk for the first time here. Since then, the stock price has (almost) only gone in one direction, gaining more than 400% to date.

Last year, the Danish diabetes specialist caused a stir with its „weight-loss injection.“ Since autumn, Novo Nordisk has even become the most valuable company in Europe. And there is still no end in sight to the success story.

World market leader in insulin preparations In case you are not familiar with Novo Nordisk, let me introduce the company to you briefly. The Danish pharmaceutical company is the world’s leading manufacturer of insulin preparations and injection systems for the treatment of diabetes, with a market share of around one third.

According to health experts, the number of diabetics worldwide is expected to increase by around 50% to 700 million by 2045. Novo Nordisk currently serves around 26 million patients. This also presents great growth potential for the coming years.

Annual forecast raised The company received a significant boost in growth from the „weight-loss injection.“ This is evident from the results that Novo Nordisk presented a few days ago. Thanks to the enormous success of Wegovy, the company achieved record sales and profits last year.

Sales increased by 36% to 232.3 billion Danish kroner (31.2 billion euros) on a currency-adjusted basis. Operating profit even improved by 44% to 102.7 billion Danish kroner (13.8 billion euros). For this year, the company is aiming for further growth and expects a currency-adjusted increase in sales of 18 to 26%. Operating profit is expected to grow by 21 to 29%.

Novo Holdings acquires Catalent Novo Nordisk wants to further expand the production of Wegovy. In the US, the „weight-loss injection“ will also be offered with a lower dosage. This is in line with the news that caught attention at the start of the week.

Novo Holdings, the investment company that controls Novo Nordisk, is acquiring US company Catalent for $11.5 billion. The contract manufacturer fills injection pens with Wegovy. Three filling lines are to be sold to Novo Nordisk after the deal is completed. This is how the company wants to further increase production and meet the high demand.


Green light for a continuation of the impressive upward trend After the presentation of the figures, the Novo Nordisk stock broke out of the sideways movement of the past weeks and has dynamically reached new highs. After this strong trend signal, everything points to a continuation of the impressive upward trend.

The post Novo Nordisk: The success story continues appeared first on Investor Verlag.